Afabicin is under clinical development by Debiopharm International and currently in Phase II for Skin And Skin Structure Infections (SSSI) Caused By Bacteria. According to GlobalData, Phase II drugs for Skin And Skin Structure Infections (SSSI) Caused By Bacteria have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Afabicin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Afabicin overview

Debio-1450 (previously AFN-1720) is under development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), Staphylococcus infections like methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), and bone and Joint infections (osteomyelitis). The drug candidate is administered intravenously and orally in the form of the solution and capsule. Debio-1450 is a prodrug of AFN-1252 (Debio-1452), It acts by targeting enoyl-acyl carrier protein reductase (FabI).

Debiopharm International overview

Debiopharm International, a subsidiary of Debiopharm Group, focuses on development and manufacture of drugs for oncology and bacterial infections. The company offers Oxaliplatin and Triptorelin drugs. It is investigating proteins, peptides and small molecules to treat cancers, solid tumors, bone and joint infections, and gastrointestinal disorders. Debiopharm is headquartered in Lausanne, Switzerland.

For a complete picture of Afabicin’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.